Data of Sotagliflozin presented at ADA

Lexicon Pharmaceuticals announced data from its two pivotal sotagliflozin studies, inTandem1 and inTandem2, in type 1 diabetes at the 77th American Diabetes Association (ADA) Scientific Sessions in San Diego, CA. Sotagliflozin is a first-in-class, oral dual inhibitor of SGLT1 and SGLT2. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.

Collectively, 24-week data from the two pivotal inTandem1 and inTandem2 studies for sotagliflozin in patients with type 1 diabetes demonstrated the following:

• Sotagliflozin 200 mg and 400 mg on top of optimized insulin significantly reduced A1C compared to placebo (p<0.001 in both studies).
• Sotagliflozin was generally well tolerated. In both studies, there was a low rate of severe hypoglycemia, which occurred less frequently on sotagliflozin than placebo in three of four arms across the two studies. In both studies, there was a low diabetic ketoacidosis (DKA) rate (0.4% to 3.1% over 24 weeks) that was higher for patients on insulin pump versus multiple dose injections (MDI).